Compare iShares China Large-Cap ETF (FXI) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Johnson & Johnson — how do they compare? iShares China Large-Cap ETF trades at $35.23, while Johnson & Johnson trades at $261.24 (market cap $626.09B). The key difference: Johnson & Johnson pays a 2.06% dividend while iShares China Large-Cap ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| FXI | JNJ | |
|---|---|---|
52-Week High | $41.75 | $267.24 |
52-Week Low | $31.59 | $172.78 |
Market Cap | — | $626.09B |
Volume | — | 6,156,228 |
Sector | — | Health |
Enterprise Value | — | $654.37B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI, the iShares China Large-Cap ETF, trades at $35.205, down 3.52% amid broader pressure on Chinese equities. Technical indicators show a bullish overall signal with strong moving average support, though oscillators are neutral. Recent news highlights China's export strength and AI-driven manufacturing rebound, while the ETF offers exposure to state-backed economic initiatives and upcoming dividend payments.
The outlook for FXI hinges on China's economic stabilization efforts and global demand for tech exports. Investment opportunities include diversification from US markets and exposure to AI hardware growth, but risks include US-China tensions, regulatory uncertainty, and value trap potential in Chinese equities.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
